

### Disease Burden of PTSD in the US **Military**

Michael C. Freed, Ph.D. **Clinical Research Psychologist** DoD Deployment Health Clinical Center, Walter Reed Army Medical Center

**Assistant Professor (Research)** Department of Psychiatry, Uniformed Services University of the Health Sciences (USUHS)

#### **Scientist**

Center for the Study of Traumatic Stress, USUHS

The views expressed in this presentation are those of the authors and do not necessarily represent the official policy or position of the Deployment Health Clinical Center, Walter Reed Army Medical Center, USUHS, Department of Defense, or the United States



### **Co-Authors**



Xian Liu, Ph.D. (1,2)
Phoebe Kuesters, BA (1)
Kristie L. Gore, Ph.D. (1,2)
Rachel Goldberg, BA (1)
Charles C. Engel, MD, MPH, COL, MC, USA

• (1) Deployment Health Clinical Center, Walter Reed Army Medical Center

(2) Department of Psychiatry & Center for the Study of Traumatic Stress (CSTS), Uniformed Services University of the Health Sciences



# **Objectives**

 Define the Disability Adjusted Life Year (DALY) as a disease-generic estimate of disease burden.

- Present the parameters necessary to calculate the disease burden of PTSD.
- Present coarse disease burden estimates of PTSD in the US military.

# Why Assess Disease Burden?

- Quantify a "missed opportunity" or "lost potential" (e.g., years of life lost) resulting from a particular disease.
- Advocacy for resource allocation—prioritize importance of disease at the population-level.
- Utilitarian metric, to maximize the health of a society.
- Measured alone, disease <u>pervasiveness</u>, <u>persistence</u>, and <u>impact</u> do not sufficiently capture population health.
- **X** Disease burden combines

# Why Assess Disease Burden?

An example: Ischemic Heart Disease\* (IHD)

IHD ranks as the #1 most "burdensome" disease in the US.

Affects both length (mortality) and health-related quality of life

(morbidity). <b>Pervasive</b> (incidence)	Male	Female	Total
	860,527 (0.66%)	532,499 (0.39%)	1,393,026 (0.53%)

Persistent

Course (all ages)

2 years

No. of Deaths Yrs of Life Lost Disability Weight (Morbidity)\*

2,858,744
\*IHD includes and combined A2018 MI, Angina 6 spar prior to final year pale Heart

(Michaud et al., 2006)

# Why Assess Disease Burden?

- Depression ranks as #4, on the same list as IHD (Michaud et al., 2006).
- How can a non-fatal disease be compared to IHD?
  - Especially when relatively few deaths are attributable to depression.
  - We do not typically think that years of life lost is on the same scale as health-related quality of life.
- Disease burden measures populationlevel morbidity and mortality burdens

- > PTSD Burden in the US (Michaud et al., 2006)
  - Ranks 15<sup>th</sup> (all races, both sexes, just under IHD but above HIV) in terms of morbidity.
  - Ranks 17<sup>th</sup> in total disease burden (morbidity + mortality burden) in women.
- **★** Military
  - More pervasive (relatively speaking)
  - More persistent (combat PTSD)
  - More impactful

#### **\*PERVASIVE**

- Prevalence
  - Vietnam Veterans (NVVRS; Kulka et al., 1990): 9-15% current
  - Desert Storm (as reported in Engel, 2006): 7-15%
  - OEF/OIF (as reported in Hoge et al., 2004): 6-20%
  - VA Primary Care (data collected in 1999; in Magruder et al., 2005): 12%
  - 3 DoD PC Clinics (data collected 2005; Gore et al., in press): 9%
- Incidence (Smith et al., 2008)
  - New onset 7.6-8.7% in deployers
  - New onset 2.3-3.0% in non deployers
  - New onset within a 2.7 years (mean) timeframe

#### **\*PERSISTENT**

- US Disease burden (Michaud et al., 2006):
  - 4 years (males)
  - 5 years (females)
- NCS (Kessler et al., 1995):
  - 3 years in treatment
  - 5.33 no treatment
- NVVRS & HVVP (from Schnurr et al., 2003): 18.54 years



#### **\*IMPACTFUL**

- Decrements in quality of life
  - Symptom severity correlated with poorer functioning (Magruder et al., 2005)
  - Symptom improvement was synchronous (vs lagged) with improvement in QoL (Schnurr et al., 2006)
- Other physical and mental health problems (Grieger et al., 2006; Gillock et al., 2005; Schnurr & Green, 2004)
- Increased use of medical services (Gillock et al., 2005)
- Increased employment absenteeism and higher medical costs (Berndt et al., 2000; Walker et al., 2003)

#### **\*TREATABLE**

- Psychotherapy (Bradley et al., 2005; Bisson et al., 2007)
- Pharmacotherapy (Davidson, 2006; Ipser et al., 2006; Davis et al., 2006)


#### PREVENTABLE?



"Could we up the dosage? I still have feelings."


- Summary measure of population health that estimates the "gap" or difference between actual population health and some specified norm or goal (WHO, 2001).
- Morbidity + Mortality

Age




Valuing health... morbidity

 How many years in a disease state (i.e., disability) is equivalent to 1 year of perfect health for a given person with the disease?




 = Mortality + Morbidity Burden on the same scale.





### Disability Adjusted Life Year (DALY)



### **How Health is Valued**


#### **Example of a Person Tradeoff**

(adapted from Freed et al., in press; Sanderson & Andrews, 2001)

#### Intervention A

Extend the life of 1000 healthy people for 1 year. All 1000 people will die after 1-year. If don't choose Intervention A, then

all will die today.



#### **Intervention B**

Extend the life of *n* individuals with the disabling condition of interest for 1-year. All *n* individuals will die after 1-year. If don't choose Intervention B, then all will die today.

Disability weight = 1-1000/n, where the respondent is indifferent between A and B. It is a ratio of 1000 : n, where the minimum n = 1000 (best health) and the maximum n = 1 million (indicating worst health). The disability weight therefore falls

### **Method**

#### **\* Pervasiveness: Incidence**

- <u>Provider diagnosis</u> from Defense Medical Epidemiological Database (DMED)
  - Ambulatory data by branch and age in 2007
  - First occurrence diagnosis ICD 309.81
- <u>Self-report questionnaire</u> from the Millennium Cohort Study (MCS), sensitive criteria (Smith et al., 2008)
  - By branch
  - PCL-C with DSM-IV criteria (at least moderate distress)

#### **★ Impact: Disability Weights**

- GBD (estimation): 0.11 (Murray & Lopez, 1996)
- Replication (actual PTO): 0.66 (Sanderson & Andrews, 2001)

### Method

#### **\*Persistence**

- GBD: 4 years (males), 5 years (females)
- NCS: 3 years in treatment & 5.33 no treatment (Kessler et al., 1995)
- NVVRS & HVVP: 18.54 years (from Schnurr et al., 2003)
- PTSD screener study: 38% combat PTSD (Gore et al., in press)
- Our estimate: 9.67 years

### **™Mortality: Years in PTSD vs. Not**


 Assessed with a life table using rates from a US white male population in CY2004.

### Method


# Model parameters for sensitivity analyses

- Base Case
  - Incidence from DMED
  - Disability weight: 0.66 Sanderson & Andrews (2001)
- Worst Case
  - Incidence from MCS, sensitive criteria
  - Disability weight: 0.66
- Best Case
  - Incidence from DMED
  - Disability weight from GBD: 0.11


### Results



### Results



### Results



### EXECUTIVE DECISION MARING SYSTEM

# Dussion & Conclusion

- \*Prioritize diseases based on pervasiveness, persistence, and impact
- ➤ Differences in service branches due to differences in pervasiveness (in our model)
- ★If model parameters change, then estimates change
  - PTSD in military (scaled) vs. IHD in general population
  - Disability weight: 0.11 (estimation in GBD) vs.
     0.66 (actual PTO in replication study)

### Limitations

- Service utilization from DMED data has its drawbacks
- ★ Patchwork model parameters
- ★ US white male life table may not be representative
  of a military population
- Disability weights may not reflect military preferences
- ★ We do not have the overall disability measurements within the military. Thus, percentages of YLDs may be inflated.
- be inflated.

  \*Crude sensitivity analysis did not account for discounting or age weighting

### **Future Directions**

- A comprehensive dataset to include mortality and morbidity in servicemembers and veterans.
- Service member preferences for most relevant diseases within DoD and VA.
- Comparison of resources devoted to the prevention, treatment, and researching of the diseases being studied.
- Longitudinal trend in disease burden as a function of resources devoted to prevention, treatment, and research.

### Questions, Information, & **Assistance**

#### **DoD Deployment Health Clinical Center**

Walter Reed Army Medical Center

Building 2, Room 3E01

6900 Georgia Ave, NW

Washington, DC 20307-5001 (202) 782-6563

E-manspondence regarding this presentation:

Website: www.PDHealth.mil Michael C. Freed, Ph.D., EMT-B

Clinical Research Psychologist

Deployment Health Clinical Center

(202) 356-1012 x40318

Michael.Freed@amedd.army.mil

**Provider Helpline** 1-866-559-1627

**Patient Helpline** 1-800-796-9699



# ncidanca Patas Ilsad

mciaem	Le no	ates us	eu
Branch	DMED	MCS 1-Year (Smith et al., 2008)	US Burden of Disease (Michaud et al., 2006)

1.31%

1.82%

1.07%

0.67%

1.37%

0.80%

1.35%

0.36%

0.27%

1.04%

AII

**USA** 

**USN** 

**USAF** 

**USMC** 

(Males)

**US Population** 

**US Population** 

(Females)

**Population** 

Size

1,360,798

510,390

334,077

333,664

182,667

129,810,215

135,473,568

0.09%

0.23%